Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to spend time promenading with the official mascot, manicure the Pharmalot campus grounds, and have a listening party with Mrs. Pharmalot. And what about you? This remains a fine time to enjoy the great outdoors — remember, beaches and lakes are beckoning. You could catch up on your reading. Or make plans with someone special. Well, whatever you do, have a grand time. But be safe. By the way, there is an extended break on this side of the pond, after which we will hit the proverbial pause button to observe ancient rituals, so a colleague will fill in for us. Meanwhile, enjoy and see you next year. …

House lawmakers have requested data and documents from the Food and Drug Administration related to the agency’s controversial accelerated approval of Biogen’s (BIIB) new Alzheimer’s drug, STAT writes. The House committees have already requested documents from Biogen, but this is the first public request by congressional investigators directly to the agency. The request cites a STAT story that revealed Biogen had an off-the-books meeting with a key FDA regulator ahead of the approval last June.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment